Epigenetic alterations of the Igf2 promoter and the effect of miR‑483‑5p on its target gene expression in esophageal squamous cell carcinoma

Zhang,Han; Shi,Xiaowei; Chang,Weidong; Li,Yingying; Wang,Li; Wang,Linsong

doi:10.3892/mmr.2017.8134

Epigenetic alterations of the Igf2 promoter and the effect of miR‑483‑5p on its target gene expression in esophageal squamous cell carcinoma

Authors:
- Han Zhang
- Xiaowei Shi
- Weidong Chang
- Yingying Li
- Li Wang
- Linsong Wang
View Affiliations

Affiliations: School of Life Sciences and Biotechnology, Sanquan College of Xinxiang Medical University, Xinxiang, Henan 453007, P.R. China, College of Life Science, Henan Normal University, Xinxiang, Henan 453007, P.R. China
Published online on: November 22, 2017 https://doi.org/10.3892/mmr.2017.8134
Pages: 2251-2256
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most widespread malignancies in China. MicroRNAs (miRNAs/miRs) are endogenous evolutionarily‑conserved small non‑coding RNAs that are able to regulate ESCC formation and deterioration by negatively regulating specific target genes. In the present study, the expression levels of miR‑483‑5p and its associated mRNAs were measured by quantitative polymerase chain reaction (PCR) analysis, and the methylation levels of the insulin‑like growth factor 2 (Igf2) promoter were detected via the methylation‑specific PCR method in serum and tissues from patients with ESCC. The results demonstrated that the expression level of miR‑483‑5p was significantly upregulated in preoperative serum and cancer tissues from patients with ESCC (P<0.01), and the miR‑483‑5p expression levels were correlated with the tumor, node, metastasis stage (P<0.05) and lymph node metastasis (P<0.05). In addition, the mRNA levels of miR‑483‑5p target genes (Rho GDP dissociation inhibitor α, activated leukocyte cell adhesion molecule, and suppressor of cytokine signaling 3) in cancer tissues were significantly decreased compared with adjacent non‑cancerous tissues. These results indicated that miR‑483‑5p and its target genes may be involved in the developmental process of ESCC. The Igf2 levels in cancer tissues were significantly increased compared with adjacent non‑cancerous tissues (P<0.01). Additionally, the methylation levels of the Igf2 promoter region were 31.82 and 54.55% in cancer tissues and adjacent non‑cancerous tissues, respectively, suggesting that low methylation of the Igf2 gene promoter region may promote the expression of Igf2 and miR‑483‑5p; this, in turn, induces the degradation of miR‑483‑5p target genes, and leads to the upregulation of oncogenes and the downregulation of tumor suppressors, which promotes the development of ESCC.

View Figures

View References

1	Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013. View Article : Google Scholar : PubMed/NCBI
2	Wen SW, Zhang YF, Li Y, Liu ZX, Lv HL, Li ZH, Xu YZ, Zhu YG and Tian ZQ: Characterization and effects of miR-21 expression in esophageal cancer. Genet Mol Res. 14:8810–8818. 2015. View Article : Google Scholar : PubMed/NCBI
3	Chen W, He Y, Zheng R, Zhang S, Zeng H, Zou X and He J: Esophageal cancer incidence and mortality in China, 2009. J Thorac Dis. 5:19–26. 2013.PubMed/NCBI
4	Peng JZ, Xue L, Liu DG and Lin YH: Association of the p53 Arg72Pro polymorphism with esophageal cancer in Chinese populations: A meta-analysis. Genet Mol Res. 14:9024–9033. 2015. View Article : Google Scholar : PubMed/NCBI
5	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
6	Garzon R and Croce CM: MicroRNAs and cancer: Introduction. Semin Oncol. 38:721–723. 2011. View Article : Google Scholar : PubMed/NCBI
7	Mulrane L, Klinger R, McGee SF, Gallagher WM and O'Connor DP: microRNAs: A new class of breast cancer biomarkers. Expert Rev Mol Diagn. 14:347–363. 2014. View Article : Google Scholar : PubMed/NCBI
8	Ma J and Li X: MicroRNAs are involved in the toxicity of microcystins. Toxin Rev. 36:165–175. 2017. View Article : Google Scholar
9	Fu H, Tie Y, Xu C, Zhang Z, Zhu J, Shi Y, Jiang H, Sun Z and Zheng X: Identification of human fetal liver miRNAs by a novel method. FEBS Lett. 579:3849–3854. 2005. View Article : Google Scholar : PubMed/NCBI
10	De-Ugarte L, Yoskovitz G, Balcells S, Güerri-Fernández R, Martinez-Diaz S, Mellibovsky L, Urreizti R, Nogués X, Grinberg D, García-Giralt N and Díez-Pérez A: miRNA profiling of whole trabecular bone: Identification of osteoporosis-related changes in miRNAs in human hip bones. BMC Med Genomics. 8:752015. View Article : Google Scholar : PubMed/NCBI
11	Veronese A, Lupini L, Consiglio J, Visone R, Ferracin M, Fornari F, Zanesi N, Alder H, D'Elia G, Gramantieri L, et al: Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res. 70:3140–3149. 2010. View Article : Google Scholar : PubMed/NCBI
12	Wang C, Sun Y, Wu H, Zhao D and Chen J: Distinguishing adrenal corticalcarcinomas and adenomas: A study of clinicopathological features and biomarkers. Histopathology. 64:567–576. 2014. View Article : Google Scholar : PubMed/NCBI
13	Li HY, Liu YC, Bai YH, Sun M, Wang L, Zhang XB and Cai B: SNP at miR-483-5p-binding site in the 3′-untranslated region of the BSG gene is associated with susceptibility to esophageal cancer in a Chinese population. Genet Mol Res. 15:1–10. 2016.
14	Baba Y, Watanabe M and Baba H: A review of the alterations in DNA methylation in esophageal squamous cell carcinoma. Surgery today. 43:1355–1364. 2013. View Article : Google Scholar : PubMed/NCBI
15	Toh Y, NEgashira A and Yamamoto M: Epigenetic alterations and their clinical implications in esophageal squamous cell carcinoma. Gen Thorac Cardiovasc Surg. 61:262–269. 2013. View Article : Google Scholar : PubMed/NCBI
16	Wang K, Johnson A, Ali SM, Klempner SJ, Bekaii-Saab T, Vacirca JL, Khaira D, Yelensky R, Chmielecki J, Elvin JA, et al: Comprehensive genomic profiling of advanced esophageal squamous cell carcinomas and esophageal adenocarcinomas reveals similarities and differences. Oncologist. 20:1132–1139. 2015. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR and Hanahan D: MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 23:2152–2165. 2009. View Article : Google Scholar : PubMed/NCBI
19	Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson BG and Sidhu SB: miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res. 15:7684–7692. 2009. View Article : Google Scholar : PubMed/NCBI
20	Li F, Ma N, Zhao R, Wu G, Zhang Y, Qiao Y, Han D, Xu Y, Xiang Y, Yan B, et al: Overexpression of miR-483-5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF-β stimulated HSCs in transgenic mice. Cell Mol Med. 18:966–974. 2014. View Article : Google Scholar
21	Ma N, Wang X, Qiao Y, Li F, Hui Y, Zou C, Jin J, Lv G, Peng Y, Wang L, et al: Coexpression of an intronic microRNA and its host gene reveals a potential role for miR-483-5p as an IGF2 partner. Mol Cell Endocrinol. 333:96–101. 2011. View Article : Google Scholar : PubMed/NCBI
22	Srinivasan S, Selvan ST, Archunan G, Gulyas B and Padmanabhan P: MicroRNAs-the next generation therapeutic targets in human diseases. Theranostics. 3:930–942. 2013. View Article : Google Scholar : PubMed/NCBI
23	Song Q, Xu Y, Yang C, Chen Z, Jia C, Chen J, Zhang Y, Lai P, Fan X, Zhou X, et al: miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. Cancer Res. 74:3031–3042. 2014. View Article : Google Scholar : PubMed/NCBI
24	Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Solé M, Thung S, Moyano S, Toffanin S, Mínguez B, et al: IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. Hepatol. 52:550–559. 2010. View Article : Google Scholar
25	Verma A, Shukla NK, Deo SV, Gupta SD and Ralhan R: MEMD/ALCAM: A potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology. 68:462–470. 2005. View Article : Google Scholar : PubMed/NCBI
26	Eskandari L, Akbarzadeh A, Zarghami N and Rahmati-Yamchi M: Gold nanoprobe-based method for sensing activated leukocyte cell adhesion molecule (ALCAM) gene expression, as a breast cancer biomarker. Artif Cells Nanomed Biotechnol. 45:277–282. 2017. View Article : Google Scholar : PubMed/NCBI
27	Hui B, Chen X, Hui L, Xi R and Zhang X: Serum miRNA expression in patients with esophageal squamous cell carcinoma. Oncol Lett. 10:3008–3012. 2015.PubMed/NCBI
28	Shi L, Liu S, Zhao W and Shi J: miR-483-5p and miR-486-5p are down-regulated in cumulus cells of metaphase II oocytes from women with polycystic ovary syndrome. Reprod Biomed Online. 31:565–572. 2015. View Article : Google Scholar : PubMed/NCBI
29	Jorgensen SB, O'Neill HM, Sylow L, Honeyman J, Hewitt KA, Palanivel R, Fullerton MD, Öberg L, Balendran A and Galic S: Deletion of skeletal muscle SOCS3 prevents insulin resistance in obesity. Diabetes. 62:56–64. 2013. View Article : Google Scholar : PubMed/NCBI